GlaxoSmithKline PLC
12 February 2007
Issued - 12th February 2007, London
GLAXOSMITHKLINE PLC ANNOUNCES
CHANGE TO THE BOARD OF DIRECTORS
GlaxoSmithKline plc (GSK) announces that Dr Stephanie Burns has been appointed
as a Non-Executive Director and will join the Board of the Company with
immediate effect.
Dr Burns is Chairman, President and Chief Executive Officer of Dow Corning
Corporation. An expert in organic chemistry, Dr Burns is also a member of the
American Chemical Society and sits on the executive committee of the Society of
Chemical Industry.
In commenting on the new appointment, Sir Christopher Gent, Chairman of GSK,
said:
"I am delighted that Stephanie has agreed to join the GSK Board. As a
recognised business leader of a global organisation, together with her strong
scientific background and staunch advocacy for science education, Stephanie will
bring a wealth of experience to the Board."
Dr Burns' biographical details are given below together with a table showing the
membership of the Board and its Committees with effect from 12th February 2007.
Simon Bicknell
Company Secretary
12th February 2007
NOTES
The Board has determined that Dr Burns is independent in accordance with the
Combined Code on Corporate Governance.
BIOGRAPHICAL DETAILS
Dr Stephanie Burns
Age 51. Dr Burns is Chairman, president and chief executive officer of Dow
Corning. She joined Dow Corning in 1983 as a researcher working on water based
and high temperature elastomers. She became director of Women's Health in 1994
and subsequently moved into corporate management becoming Science and Technology
Director for Europe in 1997. She was first elected to Dow Corning's Board of
Directors in December 2000, she was then elected president and chief executive
officer in February 2003, Chief Operating Officer in January 2004 and Chairman
in January 2006.
Dr Burns holds a Ph.D. in organic chemistry, with an organosilicon specialty,
from Iowa State University. She completed her post-doctoral studies at the
Universite Montpellier, Sciences et Techniques du Languedoc, France.
She is a board member of the American Chemical Society and The Conference Board
and sits on the executive committee of the Society of Chemical Industry. She
has also serves on the Michigan Molecular Institute.
BOARD AND COMMITTEE MEMBERSHIP
WITH EFFECT FROM 12TH FEBRUARY 2007
Sir Christopher Gent Chairman
Sir Ian Prosser Senior Independent Non-Executive Director
Dr J-P Garnier Chief Executive Officer
Mr J S Heslop Chief Financial Officer
Dr Moncef Slaoui Executive Director, Chairman, Research & Development
Dr Stephanie Burns Independent Non-Executive Director
Mr H Lawrence Culp Independent Non-Executive Director
Sir Crispin Davis Independent Non-Executive Director
Sir Deryck Maughan Independent Non-Executive Director
Dr Daniel Podolsky Independent Non-Executive Director
Dr Ronaldo Schmitz Independent Non-Executive Director
Mr Tom de Swaan Independent Non Executive Director
Sir Robert Wilson Independent Non-Executive Director
Board Committee Committee Chairman Members
Audit Mr Tom de Swaan Sir Deryck Maughan
Dr Daniel Podolsky
Sir Ian Prosser
Dr Ronaldo Schmitz
Sir Robert Wilson
Remuneration Sir Robert Wilson Mr H Lawrence Culp
Sir Crispin Davis
Sir Christopher Gent
Dr Ronaldo Schmitz
Nominations Sir Christopher Gent Sir Ian Prosser
Dr Ronaldo Schmitz
Corporate Responsibility Sir Christopher Gent Sir Ian Prosser
Mr Tom de Swaan
Dr Daniel Podolsky
GlaxoSmithKline enquiries:
UK Media enquiries: Philip Thomson (020) 8047 5502
Alice Hunt (020) 8047 5502
Gwenan White (020) 8047 5502
US Media enquiries: Nancy Pekarek (215) 751 7709
Mary Anne Rhyne (919) 483 2839
Patricia Seif (215) 751 7709
European Analyst/Investor enquiries: Anita Kidgell (020) 8047 5542
David Mawdsley (020) 8047 5564
Sally Ferguson (020) 8047 5543
US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002
Tom Curry (215) 751 5419
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.